David Axelrod

NY Times Discovers Obama's Favorite Utility

John Rowe photoAttentive NLPC readers were aware of the extent of Exelon Corporation’s activism to gain regulatory favor in support of “green” policies in which it reaped millions of dollars in government grants and mandates, but last week’s lengthy New York Times article about the cronyism-tainted relationship between the Chicago-based utility and the Obama administration revealed a few nuggets.

The story told how Exelon, with top executives as “early and frequent” supporters of the president as his political career ascended, were able to gain more access to the White House than others thanks to their longstanding relationships. According to one Exelon lobbyist, his employer was considered “the president’s utility.”

White House Plan to Mine Social Networks is Dangerous Because of Scope, Secrecy and Context

Facebook logoWe are happy that our August 31 report on the White House New Media operation to harvest data from social network websites is finally getting some attention. We unearthed the fact that this office is seeking a vendor capable of conducting a massive data harvesting operation, prompting concerns that the White House is seeking to identify friends and enemies.

When we posted our story, we received so many hits that it took down our server and forced us to move to a more powerful machine, but we received scant print and electronic media coverage. Today, the Washington Times covered the story on its front page, above the fold. Drudge and Lucianne linked to the story, giving it high visibility.

Big Pharma Will Be Ultimate Victim of Its Sellout on Obama Health Care Plan

phrma logoIt may be high irony, but capitalists over the decades all too often have been at odds with capitalism. That is, business organizations, for any number of reasons, have been prone to support ideas and policies whose intent is to bring free enterprise under social control. This syndrome is well and alive at a pair of prescription drug/biotechnology industry organizations: the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Pharmaceutical Industry Labor-Management Association (PILMA). Each group is working to promote a radical expansion of government involvement in health care, acting in concert with Capitol Hill Democrats and especially the Obama administration.

Syndicate content